Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-surgical liquid biopsy-guided treatment in stage III and high-risk stage II colon cancer
2019-002074-32Phase 2Active
- Sponsor
- IFOM
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine, oxaliplatin, fluorouracil, irinotecan and folinic acid in colon cancer (2 arms), sponsored by IFOM. Primary endpoint: Number of post-surgery and post-adjuvant false negative cases after a double ctDNA-negative result. Started Nov 2019; status: active.
02
Drugs
capecitabineoxaliplatinfluorouracilirinotecanfolinic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2019-002074-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002074-32.